Ultragenyx Pharmaceutical Inc
RARE33.760USD
+0.235+0.70%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
3.26BMarket Cap
LossP/E TTM
More Details of Ultragenyx Pharmaceutical Inc Company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Ultragenyx Pharmaceutical Inc Info
Ticker SymbolRARE
Company nameUltragenyx Pharmaceutical Inc
IPO dateJan 31, 2014
CEODr. Emil D. Kakkis, M.D., Ph.D.
Number of employees1294
Security typeOrdinary Share
Fiscal year-endJan 31
Address60 Leveroni Ct
CityNOVATO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94949
Phone14154838800
Websitehttps://www.ultragenyx.com/
Ticker SymbolRARE
IPO dateJan 31, 2014
CEODr. Emil D. Kakkis, M.D., Ph.D.
Company Executives of Ultragenyx Pharmaceutical Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
7.75K
-50.61%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Mr. Eric Olson
Mr. Eric Olson
Chief Business Officer, Executive Vice President
Chief Business Officer, Executive Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
By RegionUSD
Name
Revenue
Proportion
North America
102.93M
61.82%
Latin America
32.97M
19.80%
Europe
26.40M
15.86%
Japan
4.20M
2.52%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
Other
72.46%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
Other
72.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.75%
Investment Advisor/Hedge Fund
31.58%
Hedge Fund
15.20%
Individual Investor
3.48%
Research Firm
2.31%
Sovereign Wealth Fund
1.02%
Private Equity
1.02%
Pension Fund
0.52%
Bank and Trust
0.40%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
640
97.34M
100.90%
-3.53M
2025Q2
635
97.48M
101.32%
-2.63M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
10.19M
10.58%
+217.20K
+2.18%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.02M
5.21%
+106.89K
+2.18%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.27M
2.36%
+1.89M
+495.36%
Jun 30, 2025
Sands Capital Management, LLC
3.94M
4.09%
-220.08K
-5.29%
Jun 30, 2025
State Street Investment Management (US)
2.57M
2.67%
-46.25K
-1.77%
Jun 30, 2025
RTW Investments L.P.
1.71M
1.77%
--
--
Jun 30, 2025
JP Morgan Asset Management
2.60M
2.7%
+2.56M
+5502.04%
Jun 30, 2025
Baker Bros. Advisors LP
2.77M
2.88%
+1.20M
+75.92%
Jun 30, 2025
Kakkis (Emil D)
2.69M
2.79%
-31.78K
-1.17%
Mar 07, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Motley Fool Small-Cap Growth ETF
3.15%
Global X Genomics & Biotechnology ETF
2.87%
Franklin Genomic Advancements ETF
1.35%
Virtus LifeSci Biotech Products ETF
1.27%
SPDR S&P Biotech ETF
1.21%
WisdomTree BioRevolution Fund
0.88%
Touchstone Sands Capital US Select Growth ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Large Growth ETF
0.55%
Goldman Sachs Future Health Care Equity ETF
0.5%
View more
Motley Fool Small-Cap Growth ETF
Proportion3.15%
Global X Genomics & Biotechnology ETF
Proportion2.87%
Franklin Genomic Advancements ETF
Proportion1.35%
Virtus LifeSci Biotech Products ETF
Proportion1.27%
SPDR S&P Biotech ETF
Proportion1.21%
WisdomTree BioRevolution Fund
Proportion0.88%
Touchstone Sands Capital US Select Growth ETF
Proportion0.8%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.63%
First Trust Multi-Manager Large Growth ETF
Proportion0.55%
Goldman Sachs Future Health Care Equity ETF
Proportion0.5%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ultragenyx Pharmaceutical Inc?
The top five shareholders of Ultragenyx Pharmaceutical Inc are:
The Vanguard Group, Inc. holds 10.19M shares, accounting for 10.58% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.02M shares, accounting for 5.21% of the total shares.
Fidelity Management & Research Company LLC holds 2.27M shares, accounting for 2.36% of the total shares.
Sands Capital Management, LLC holds 3.94M shares, accounting for 4.09% of the total shares.
State Street Investment Management (US) holds 2.57M shares, accounting for 2.67% of the total shares.
The Vanguard Group, Inc. holds 10.19M shares, accounting for 10.58% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.02M shares, accounting for 5.21% of the total shares.
Fidelity Management & Research Company LLC holds 2.27M shares, accounting for 2.36% of the total shares.
Sands Capital Management, LLC holds 3.94M shares, accounting for 4.09% of the total shares.
State Street Investment Management (US) holds 2.57M shares, accounting for 2.67% of the total shares.
What are the top three shareholder types of Ultragenyx Pharmaceutical Inc?
The top three shareholder types of Ultragenyx Pharmaceutical Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
How many institutions hold shares of Ultragenyx Pharmaceutical Inc (RARE)?
As of 2025Q3, 640 institutions hold shares of Ultragenyx Pharmaceutical Inc, with a combined market value of approximately 97.34M, accounting for 100.90% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.43%.
What is the biggest source of revenue for Ultragenyx Pharmaceutical Inc?
In FY2025Q2, the Crysvita royalty revenue business generated the highest revenue for Ultragenyx Pharmaceutical Inc, amounting to 85.68M and accounting for 51.46% of total revenue.
